Literature DB >> 16452569

Assessing EGFR mutations.

Antonio Marchetti, Lara Felicioni, Fiamma Buttitta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16452569     DOI： 10.1056/NEJMc052564

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  54 in total

1.  MGMT promoter methylation in non-neoplastic brain.

Authors:  Chih-Yi Hsu; Hsiang-Ling Ho; Yi-Chun Chang-Chien; Yi-Wen Chang; Donald Ming-Tak Ho
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

2.  Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.

Authors:  Giuseppe Pelosi; Federica Perrone; Elena Tamborini; Alessandra Fabbri; Maria Adele Testi; Adele Busico; Giulio Settanni; Benedetta Picciani; Enrica Bovio; Angelica Sonzogni; Barbara Valeri; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-01-27       Impact factor: 4.064

Review 3.  [Molecular methods in the diagnosis of sarcoma].

Authors:  S Merkelbach-Bruse; E Wardelmann; H Künstlinger; R Büttner; H-U Schildhaus
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

4.  Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

Authors:  Rom S Leidner; Pingfu Fu; Bradley Clifford; Ayad Hamdan; Cheng Jin; Rosana Eisenberg; Titus J Boggon; Margaret Skokan; Wilbur A Franklin; Federico Cappuzzo; Fred R Hirsch; Marileila Varella-Garcia; Balazs Halmos
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

5.  Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.

Authors:  M I Galleges Ruiz; K Floor; S M Steinberg; K Grünberg; F B J M Thunnissen; J A M Belien; G A Meijer; G J Peters; E F Smit; J A Rodriguez; G Giaccone
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

6.  Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.

Authors:  Vassiliki Kotoula; Elpida Charalambous; Bart Biesmans; Andigoni Malousi; Eleni Vrettou; George Fountzilas; George Karkavelas
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

7.  A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

Authors:  E-H Tan; R Ramlau; A Pluzanska; H-P Kuo; M Reck; J Milanowski; J S-K Au; E Felip; P-C Yang; D Damyanov; S Orlov; M Akimov; P Delmar; L Essioux; C Hillenbach; B Klughammer; P McLoughlin; J Baselga
Journal:  Ann Oncol       Date:  2010-02       Impact factor: 32.976

8.  Mutation detection by real-time PCR: a simple, robust and highly selective method.

Authors:  John Morlan; Joffre Baker; Dominick Sinicropi
Journal:  PLoS One       Date:  2009-02-25       Impact factor: 3.240

9.  Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.

Authors:  Hongdo Do; Alexander Dobrovic
Journal:  Mol Cancer       Date:  2009-10-08       Impact factor: 27.401

10.  Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.

Authors:  J-J Patard; N Rioux-Leclercq; D Masson; S Zerrouki; F Jouan; N Collet; C Dubourg; B Lobel; M Denis; P Fergelot
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.